Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Allarity Therapeutics, Inc. Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement April 29, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) April 17, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces 1-for-20 Reverse Stock Split April 04, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer March 27, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) March 25, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update March 08, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics to Present at Biomarkers 2024 February 28, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor December 12, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic December 05, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics to Present at Biomarkers Europe 2023 October 02, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib August 30, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics July 31, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives July 24, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering July 06, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients July 05, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Reverse Stock Split of Common Stock June 28, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split June 27, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders June 20, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting May 30, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering April 19, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting April 11, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies March 28, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Reverse Stock Split of Common Stock March 24, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors March 20, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders January 20, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date December 01, 2022 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Reports Third Quarter 2022 Financial Results November 15, 2022 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders November 07, 2022 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements October 11, 2022 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.